← Leaderboards
Rona Yaeger
Sloan-Kettering Inst Can Research
$3,362,000
Attributed
$4,005,718
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2019–25$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,005,718 · 4
By mechanism
R01$3,800,018 · 3
R21$205,700 · 1
Top collaborators
- Andrea Cercek2 shared
- Sarat Chandarlapaty1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- David B. Solit$21,393,031
- Craig B Thompson$56,520,903
- Mithat Gonen$8,869,475
- Arvin Dar$9,617,218
- Mengmeng Du$2,352,665
Others in their field
Other Emerging Leaders on “Colorectal Cancer”
- Xingyi Guo · Vanderbilt University Medical Center$6,823,295
- Yin Cao · Washington University$6,585,192
- Mingyang Song · Massachusetts General Hospital$6,525,328
- Stephanie L. Schmit · H. Lee Moffitt Cancer Ctr & Res Inst$6,323,663
- Kamila Naxerova · Massachusetts General Hospital$5,403,066
- Dustin A Deming · University Of Wisconsin-Madison$5,391,375
Research focus
Colorectal CancerTargeted TreatmentResistanceResponseSamplingTumorColon Cancer PatientsResistance MechanismRecurrenceIncidencePathway InteractionsToxic EffectMediatingOncogenesSignal PathwayImproved OutcomeSignal TransductionReceptor Protein-Tyrosine KinasesGenomicsGrowthBraf GenePatient-Focused OutcomesMutationCancer Etiology
Grant awards (10)
Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.$482,236
R01 · FY2025 · CA · contact PI
Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer$402,600
R01 · FY2025 · CA
Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response$205,700
R21 · FY2025 · CA · contact PI
Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer$402,600
R01 · FY2024 · CA
Exploiting the distinct genomics and signaling of colorectal cancers to effectively target ERK$237,941
R01 · FY2024 · CA · contact PI
Exploiting the distinct genomics and signaling of colorectal cancers to effectively target ERK$254,557
R01 · FY2023 · CA · contact PI
Exploiting the distinct genomics and signaling of colorectal cancers to effectively target ERK$505,021
R01 · FY2022 · CA · contact PI
Exploiting the distinct genomics and signaling of colorectal cancers to effectively target ERK$505,021
R01 · FY2021 · CA · contact PI
Exploiting the distinct genomics and signaling of colorectal cancers to effectively target ERK$505,021
R01 · FY2020 · CA · contact PI
Exploiting the distinct genomics and signaling of colorectal cancers to effectively target ERK$505,021
R01 · FY2019 · CA · contact PI